Title:
FINE PARTICLE POWDER-TYPE MUCOSAL VACCINE
Document Type and Number:
WIPO Patent Application WO/2022/168889
Kind Code:
A1
Abstract:
When this vaccine is administered to the nasal cavity, etc., a vaccine component stays in the nasal cavity or the pharynx, providing a means for heightening the effects of vaccine administration such as induction of immunity. It was confirmed that an antibody-production-inducing effect is greatly enhanced by a synergistic effect achieved by adding a synthetic peptide, a mixed lipid, β-1,3-glucan or inulin, and an amino acid to an antigen protein.
More Like This:
Inventors:
KIDO HIROSHI (JP)
SUZUKI KOICHI (JP)
SAKAI SATOKO (JP)
KIMOTO TAKASHI (JP)
SUZUKI KOICHI (JP)
SAKAI SATOKO (JP)
KIMOTO TAKASHI (JP)
Application Number:
PCT/JP2022/004130
Publication Date:
August 11, 2022
Filing Date:
February 02, 2022
Export Citation:
Assignee:
APPLIED MEDICAL ENZYME RES INSTITUTE CORPORATION (JP)
International Classes:
A61K39/39; A61K9/12; A61K9/14; A61K47/18; A61K47/36; A61P11/00; A61P31/16; A61K39/00; A61K39/145; C07K7/08; C07K14/00
Domestic Patent References:
| WO2009123119A1 | 2009-10-08 | |||
| WO2017047089A1 | 2017-03-23 |
Foreign References:
| JP2011057605A | 2011-03-24 | |||
| CN104208029A | 2014-12-17 | |||
| JPS60193925A | 1985-10-02 |
Other References:
ASAGIRI KIMIO: "Inulin", THE JAPANESE JOURNAL OF SURGICAL METBOLISM AND NUTRITION, NIHON GEKA TAISHA EIYO GAKKAI, TOKYO, JP, vol. 54, no. 3, 1 August 2020 (2020-08-01), JP , pages 160 - 161, XP055955621, ISSN: 0389-5564, DOI: 10.11638/jssmn.54.3_160
Attorney, Agent or Firm:
HIROTA, Masanori (JP)
Download PDF: